Abstract:Inflammation and neuroinflammation are critical mechanisms in the generation of neuropathic pain that is experienced in several chronic diseases. The aberrant inflammation that triggers this pathophysiologic process can be tracked down to an exacerbated immune response, which establishes a vicious cycle and continuously recruits inflammatory cells by inducing chronic tissue damage. Recently, impairment of the cellular and molecular machinery orchestrated by specialized pro-resolving mediators (SPMs)—i.e., endogenous lipids termed resolvins, protectins, maresins, and lipoxins that confine the inflammatory cascades in space and time during the “resolution of inflammation”–has emerged as a crucial event in the derangement of the inflammatory homeostasis and the onset of chronic inflammation and pain. Indeed, a deviant inflammatory response that is not adequately controlled by the resolution network leads to the overproduction of pro-inflammatory eicosanoids that, opposite to SPMs, lead to neuropathic pain. Interestingly, in the last two decades convincing evidence has demonstrated that SPMs antagonize the in vivo activity of pro-inflammatory eicosanoids and, overall, exert potent anti-hyperalgesic effects in a number of pain-associated paradigms of disease, such as arthritis and chemotherapy-induced peripheral neuropathy, as well as in many experimental models of pain like mechanical allodynia, chemical pain, heat hypersensitivity and phase 1 and 2 inflammatory pain. Of note, accumulated evidence supports a synergy between SPMs and other signalling pathways, such as those mediated by transient receptor potential (TRP) channels and those triggered by opioid receptors, suggesting that the cascade of events where inflammation and pain perception take part might be ways more intricated than originally expected. Here, we aim at presenting a state-of-the-art view of SPMs, their metabolism and signalling, in the context of cellular and molecular pathways associated to neuropathic pain.

Research progress in the mechanisms and functions of specialized pro-resolving mediators in neurological diseases

Inflammation resolution and specialized pro-resolving lipid mediators in CNS diseases

Meningeal Immunity and Neurological Diseases: New Approaches, New Insights

Research progress on the role and regulatory mechanism of pathogenic Th17 cells in neuroinflammation

Neuroimmune interactions and their roles in neurodegenerative diseases

CNS and CNS Diseases in Relation to Their Immune System

Specialized pro-resolving mediator network: an update on production and actions

Role of Specialized Pro-Resolving Mediators in Neuropathic Pain

Role of Specialized Pro-Resolving Lipid Mediators in Pulmonary Inflammation Diseases: Mechanisms and Development

[Research Progress on the Mechanism of Pro-Inflammatory Regression Mediators Promoting Inflammation Regression by Regulating Immune Cells].

Role and Regulatory Mechanism of Microrna Mediated Neuroinflammation in Neuronal System Diseases

The Emerging Role of Central and Peripheral Immune Systems in Neurodegenerative Diseases

Microglia Activation, Classification and Microglia-Mediated Neuroinflammatory Modulators in Subarachnoid Hemorrhage.

Frontiers of Neurodegenerative Disease Treatment: Targeting Immune Cells in Brain Border Regions

Th17 cells and inflammation in neurological disorders: Possible mechanisms of action

Research Progress on the Role of Microglia Membrane Proteins or Receptors in Neuroinflammation and Degeneration

Specialized Pro-resolving Lipid Mediators and Glial Cells: Emerging Candidates for Brain Homeostasis and Repair

New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery

Pain-resolving immune mechanisms in neuropathic pain

The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets

Current Understanding of Platelet-Activating Factor Signaling in Central Nervous System Diseases